“Use of Ozempic is associated with changes in taste perception and reduced enjoyment of eating.”

Increased sweet taste intensity was reported at similar frequencies in all groups (Wegovy® 19.4%, Ozempic® 21.6%, Mounjaro® 21.7%; *p* = 0.489). The proportion of participants reporting increased salty taste intensity was highest in the Wegovy® group (26.7%), compared to Ozempic® (16.2%). Further analysis also found links between changes in taste perception and appetite/satiety. Participants who reported food tasting sweeter after taking GLP-1s were twice as likely to report increased satiety, 67% more likely to report a reduction in appetite, and 85% more likely to report a reduction in food cravings.

Semaglutide improved taste sensitivity, changed gene expression in the tongue that's responsible for taste perception, and changed the brain's response to sweet tastes, according to research presented Saturday at ENDO 2024, the Endocrine Society's annual meeting in Boston, Mass. Those in the treatment group experienced changes in taste perception, taste bud gene expression and brain activity in response to sweet taste stimuli.

Some people taking Ozempic, Wegovy, or Mounjaro notice that food suddenly tastes sweeter or saltier, and this subtle shift in flavor perception appears tied to reduced appetite and stronger feelings of fullness. In a study of more than 400 patients, roughly one in five experienced heightened taste sensitivity, and many reported being less hungry and more easily satisfied.

Mild side effects that have been reported with Ozempic include: gas and burping; dizziness; nausea; vomiting; diarrhea; abdominal pain; constipation; fatigue; changes in your sense of taste.

From reduced hunger to a changing palate, weight loss jabs can alter our experience and enjoyment of food. Because GLP-1s reduce the “reward value” of fatty, sugary and salty food, as well as reduce appetite, many patients go off these foods.

A new study presented at ENDO 2024 finds that semaglutide influences taste sensitivity and how the brain responds to sweet tastes. At the end of the 16-week study, researchers found that those taking semaglutide were more sensitive to tastes than those taking placebo. Brain scans demonstrated that in response to tasting a sweet solution, there was increased activity in the angular gyrus of the parietal cortex, which might alter an individual's sensation of the reward linked to sweet tastes, potentially supporting dietary changes.

Overall, around a fifth of participants said food tasted sweeter (21.3%) or saltier (22.6%) after taking a GLP-1 drug. Participants did not report any changes to their perception of bitterness or sourness. Participants who reported food tasting sweeter after taking GLP-1s were twice as likely to report increased satiety, 67% more likely to report a reduction in appetite, and 85% more likely to report a reduction in food cravings. Similarly, participants who reported food tasting saltier than before were 2.17 times more likely to report increased satiety.

Semaglutide — a popular weekly injection used for diabetes and weight loss — changes the taste sensitivity, taste perception and the brain’s response to sweet tastes in women with obesity, according to new research presented at the Endocrine Society’s annual meeting in Boston. “People with obesity often perceive tastes less ‘intensely,’ and they have an inherently elevated desire for sweet and energy-dense food,” explained Mojca Jensterle Sever, Ph.D., of the University Medical Centre in Ljubljana, Slovenia.

It's clear that Ozempic plays a role in curbing appetite and contributes to feelings of fullness. However, other reports suggest that Ozempic may not only remove the pleasure you derive from food but from other activities as well. The medication could alter the way food tastes and may even impact your ability to derive pleasure from activities you enjoy.

GLP-1 receptor agonists like semaglutide work by activating GLP-1 receptors throughout the body, including on taste bud cells and in brain regions that process taste and reward. The mechanism involves altered gene expression in taste receptors and modified neural signaling in areas like the angular gyrus, which processes the hedonic (reward) value of food. This altered reward signaling, combined with increased taste sensitivity to certain flavors, contributes to reduced appetite and food cravings—particularly for sweet and fatty foods.

Anhedonia—a reduced ability to feel pleasure—can manifest as emotional flatness for some people on GLP-1 medications. These medications act on areas involved in dopamine signalling, which affects motivation, pleasure, and habit formation. Some individuals describe feeling emotionally flat, while others experience a sense of freedom from habits.